Stemline Therapeutics, Inc.
Stemline Therapeutics is a clinical-stage biopharmaceutical company developing novel oncology agents. SL-401, an interleukin-3 receptor (CD123) targeted therapy, was granted breakthrough therapy designation in blastic plasmacytoid dendritic cell neoplasm (BPDCN). The BPDCN pivotal trial met its primary endpoint; a BLA is planned. Other SL-401 trials include chronic myelomonocytic leukemia and myelofibrosis, AML, and myeloma. SL-801, a novel oral reversible XPO1 inhibitor, is in a Phase 1 trial in advanced solid tumors. SL-701, an immunotherapeutic, completed a Phase 2 trial in second-line GBM.